Johnson & Johnson says its one-shot COVID-19 vaccine is effective

Share

Paul Stoffels, vice chairman of the executive committee and chief scientific officer at Johnson & Johnson, said: "These topline results with a single-shot Covid-19 vaccine candidate represent a promising moment". "We have applied for starting trials in India". If approved, Novavax could be India's third COVID-19 vaccine. "Clearly, the Novavax vaccine prevented severe disease which is really in the end what matters the most".

An expression of interest (EOI) process will begin February 1 for pharmacies around Australia to participate in the Community Pharmacy COVID-19 Vaccination Progra.

Now the vaccine has become a headache, with questions about its effectiveness, and potential litigation because of delays in delivery to the European Union. Moderna's stock gained 8% to $172.80.

"The German questions about the AstraZeneca-Oxford vaccine, and the US FDA's apparent unwillingness to approve it, are unfortunate and may not be helpful for the FTSE 100 firm's reputation, but many other countries seem happy to keep on using it", he said.

South Korea has signed a deal with the firm to purchase doses for ten million people.

Pharmacy Guild of Australia national president George Tambassis said the network of 5800 pharmacies across Australia would provide better access to the vaccine for more people.

Samsung Galaxy S21 set to sell in 130 countries by next month
For below Rs. 7,000, the Samsung Galaxy M02 will offer a 6.5-inch HD+ display, a 5,000mAh battery, and possibly dual rear cameras. Samsung has also confirmed that it plans to expand the foldable category in 2021 with new Galaxy Z Fold and Galaxy Z Flip models.

"The key is not only overall efficacy but specifically efficacy against severe disease, hospitalization, and death", said Walid Gellad, a health policy associate professor at the University of Pittsburgh.

Unlike the Pfizer, Moderna and AstraZeneca vaccines, which deliver the genetic instructions that make human cells create a key protein of the virus, the Novavax shot injects the proteins directly into the body to evoke an immune response.

Scientists continue to be concerned about the South African strain of the virus and one that emerged in Brazil, with the expectation that these strains will not work as well with current vaccines.

"What we are learning is there is different efficacy in different parts of the world", Stoffels told Reuters.

There are numerous vaccines nonetheless present process trials around the globe, however exclusively three have been accredited to be used within the United Kingdom thus far. In the South Africa portion of the trial, 95% of cases were infections with the South African variant.

The announcement comes amid worry about whether a variety of vaccines being rolled out around the world will be strong enough to protect against worrisome new variants - and also the world needs new types of shoots to boost scarce supplies.

Share